Related Experiment Video
Updated: Mar 28, 2026
High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
Pediatric registries at the Food and Drug Administration: design aspects that increase their likelihood of success
Scott K Winiecki1, M Isabel Tejero-Taldo2, Debbie Avant3
1Division of Epidemiology, Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
Insights
Pediatric drug registries are more successful when they are disease-based and established before product approval. These design aspects are key for successful postmarketing studies in pediatric populations.
Area of Science:
- Pharmacovigilance
- Regulatory Science
- Pediatric Drug Development
Background:
- Postmarketing studies are crucial for evaluating drug safety and efficacy in pediatric populations.
- The US Food and Drug Administration (FDA) mandates postmarketing studies for certain drugs and biological products.
- Pediatric registries play a vital role in collecting real-world data for these studies.
Purpose of the Study:
- To identify key design features contributing to the success of pediatric registries.
- To analyze characteristics of successful versus unsuccessful postmarketing registries for drugs and biological products.
Main Methods:
- Searched the FDA Postmarketing Requirements and Commitments database for relevant pediatric registries.
- Classified registries as successful, unsuccessful, or unevaluable based on patient recruitment, deadlines, and data submission.
- Examined design aspects of successful and unsuccessful registries for commonalities.
Main Results:
- Ten out of thirty-eight identified registries met success criteria.
- Successful registries were more likely to be disease-based (60%) and pre-existing (40%).
- Unsuccessful registries lacked disease-based or pre-existing registry characteristics.
Conclusions:
- Utilizing a disease-based registry and establishing it prior to product approval are associated with higher success rates.
- These design elements may enhance the effectiveness of pediatric postmarketing studies.
- Further research with larger sample sizes could confirm these findings.
Purpose:
To determine aspects of the design of pediatric registries that contribute to the success of registries conducted as a postmarketing study following approval of drugs or biological products by the US Food and Drug Administration.
Methods:
Pediatric registries for drugs and biological products were identified by searching the US Food and Drug Administration Postmarketing Requirements and Commitments database. Based on the recruitment of patients, the meeting of predetermined deadlines, and the submission of data, we classified studies as successful, unsuccessful, or unevaluable. Design aspects of successful and unsuccessful registries were examined for commonalities.
Results:
Thirty-eight studies were identified, and ten registries met the criteria for successful. Four (40%) successful registries utilized a registry established prior to product approval, and six (60%) were disease-based. Among unsuccessful registries, none were disease-based or utilized a pre-existing registry.
Conclusions:
Characteristics identified as more common to successful registries included utilizing a disease-based registry and a registry established prior to product approval. Future studies might examine a larger sample of registries to see if these aspects consistently result in successful studies. Published 2015. This article is a U.S. Government work and is in the public domain in the USA.
